Cite
HARVARD Citation
Ikeda, T. et al. (n.d.). 1410PTumor mutation burden (TMB) estimation using small-sized targeted next-generation sequencing (NGS) to predict efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC). Annals of oncology. p. . [Online].